36.25
-1.41 (-3.74%)
| Previous Close | 37.66 |
| Open | 37.83 |
| Volume | 1,117,243 |
| Avg. Volume (3M) | 1,558,796 |
| Market Cap | 3,194,148,096 |
| Price / Earnings (Forward) | 29.67 |
| Price / Sales | 20.47 |
| Price / Book | 74.14 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Operating Margin (TTM) | -1,135.42% |
| Diluted EPS (TTM) | -1.71 |
| Quarterly Revenue Growth (YOY) | 5.00% |
| Total Debt/Equity (MRQ) | 297.04% |
| Current Ratio (MRQ) | 2.93 |
| Operating Cash Flow (TTM) | -99.23 M |
| Levered Free Cash Flow (TTM) | -64.38 M |
| Return on Assets (TTM) | -37.66% |
| Return on Equity (TTM) | -203.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Liquidia Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 1.0 |
| Average | -0.30 |
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 13.64% |
| % Held by Institutions | 65.04% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (HC Wainwright & Co., 51.72%) | Buy |
| Median | 52.00 (43.45%) | |
| Low | 44.00 (Wells Fargo, 21.38%) | Buy |
| Average | 50.75 (40.00%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 35.28 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 06 Mar 2026 | 55.00 (51.72%) | Buy | 36.03 |
| Wells Fargo | 06 Mar 2026 | 44.00 (21.38%) | Buy | 36.03 |
| BTIG | 05 Mar 2026 | 50.00 (37.93%) | Buy | 34.52 |
| Needham | 05 Mar 2026 | 54.00 (48.97%) | Buy | 34.52 |
| 25 Feb 2026 | 52.00 (43.45%) | Buy | 30.00 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ADAIR JASON | - | 38.85 | -7,301 | -283,644 |
| BOYLE DANA | - | 38.85 | -5,101 | -198,174 |
| JEFFS ROGER | - | 39.77 | -86,044 | -3,437,847 |
| KASETA MICHAEL | - | 39.23 | -161,348 | -6,444,975 |
| KREPP SARAH | - | 38.85 | -4,557 | -177,039 |
| MOOMAW SCOTT | - | 38.85 | -10,547 | -409,751 |
| SAGGAR RAJEEV | - | 38.85 | -9,220 | -358,197 |
| SCHUNDLER RUSSELL | - | 38.85 | -13,692 | -531,934 |
| Aggregate Net Quantity | -297,810 | |||
| Aggregate Net Value ($) | -11,841,562 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 39.22 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| JEFFS ROGER | Officer | 16 Apr 2026 | Automatic sell (-) | 25,000 | 41.40 | 1,035,000 |
| KASETA MICHAEL | Officer | 15 Apr 2026 | Automatic sell (-) | 139,390 | 40.12 | 5,592,327 |
| KASETA MICHAEL | Officer | 15 Apr 2026 | Option execute | 86,971 | - | - |
| JEFFS ROGER | Officer | 15 Apr 2026 | Automatic sell (-) | 25,000 | 40.12 | 1,003,000 |
| KASETA MICHAEL | Officer | 14 Apr 2026 | Automatic sell (-) | 3,000 | 38.71 | 116,130 |
| KASETA MICHAEL | Officer | 14 Apr 2026 | Option execute | 3,000 | - | - |
| JEFFS ROGER | Officer | 14 Apr 2026 | Automatic sell (-) | 3,300 | 38.71 | 127,743 |
| JEFFS ROGER | Officer | 13 Apr 2026 | Automatic sell (-) | 32,744 | 38.85 | 1,272,104 |
| SCHUNDLER RUSSELL | Officer | 13 Apr 2026 | Automatic sell (-) | 13,692 | 38.85 | 531,934 |
| SAGGAR RAJEEV | Officer | 13 Apr 2026 | Automatic sell (-) | 9,220 | 38.85 | 358,197 |
| KREPP SARAH | Officer | 13 Apr 2026 | Automatic sell (-) | 4,557 | 38.85 | 177,039 |
| KASETA MICHAEL | Officer | 13 Apr 2026 | Automatic sell (-) | 18,958 | 38.85 | 736,518 |
| BOYLE DANA | Officer | 13 Apr 2026 | Automatic sell (-) | 5,101 | 38.85 | 198,174 |
| ADAIR JASON | Officer | 13 Apr 2026 | Automatic sell (-) | 7,301 | 38.85 | 283,644 |
| MOOMAW SCOTT | Officer | 13 Apr 2026 | Automatic sell (-) | 10,547 | 38.85 | 409,751 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 27 Jan 2026 | Announcement | Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |